Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
28 RESULTS
Sort By:
Go to another page:
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Plenty of genetic risk factors for sporadic ALS are still waiting to be found, according to a new meta-analysis of GWAS data.
Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid
Heart-healthy foods containing omega-3 fatty acids, like salmon, slash risk of developing ALS by one-third.
The enzyme PARC acts as a survival factor in damaged neurons and cancer cells by targeting a pro-apoptotic protein for destruction.
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
In fruit flies that model ALS, presynaptic vesicles gather in unusually large clumps, amplifying signaling at the neuromuscular junction. Does this promote disease?
Blocking calcium-dependent protease normalizes lifespan in mouse tauopathy model.
In a large retrospective study, people with the highest plasma levels of an inflammatory protein experienced the greatest decline in reasoning abilities over the next 10 years.
Allosteric γ-secretase modulator binds an extracellular pocket on presenilin, changing the active site.
Aβ aggregates can assume a variety of structures that appear to have unique properties.
Could astrocyte neurotransmission explain memory loss in Alzheimer's disease?
Antipsychotic medications repurposed to accelerate autophagy might prevent cellular toxicity associated with mutant TDP-43.
Go to another page: